Trial Profile

An Open-Label, Randomized, Phase II/III Trial of Taxane Therapy With or Without Bavituximab for the Treatment of HER2-Negative Metastatic Breast Cancer

Status: Discontinued

Phase of Trial: Phase II/III

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bavituximab (Primary)
Indications Advanced breast cancer; HER2 negative breast cancer
Focus Therapeutic Use
Sponsors Peregrine Pharmaceuticals

Most Recent Events

07 Jul 2017 Status changed from suspended to discontinued.
13 Apr 2016 This trial was prematurely terminated in Germany, according to the European Clinical Trials Database.
08 Mar 2016 Status changed from recruiting to suspended as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com